行情

RVNC

RVNC

Revance疗法
NASDAQ

实时行情|Nasdaq Last Sale

24.60
-0.67
-2.65%
交易中 13:29 07/16 EDT
开盘
25.06
昨收
25.27
最高
25.06
最低
24.37
成交量
9.26万
成交额
--
52周最高
27.97
52周最低
9.88
市值
14.07亿
市盈率(TTM)
-6.2076
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测

分析师预测RVNC价格均价为34.70，最高价位55.00，最低价为15.00。

EPS

RVNC 新闻

更多
Is Revance Therapeutics Inc (RVNC) Going to Burn These Hedge Funds?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 07/05 19:28
Revance Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/03 06:07
Revance Therapeutics Highlights Last Patient Enrolled In Modified JUNIPER Phase 2 Upper Limb Spasticity Trial Of DaxibotulinumtoxinA For Injection
Benzinga · 06/30 20:05
Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection
Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection
Business Wire · 06/30 20:05
Revance's DAXI shows positive effect in frown line studies
Seeking Alpha - Article · 06/30 13:19
Revance Announces Results In Two Phase 2a Studies Of DaxibotulinumtoxinA For Injection For Treatment Of Forehead Lines And Crow's Feet, Respectively
- At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow's feet - -
At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow's feet - - · 06/30 12:11
Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet, Respectively
Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow’s Feet
Business Wire · 06/30 12:00
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 06/28 18:25

所属板块

生物技术和医学研究
-0.70%
制药与医学研究
-0.76%

热门股票

代码
价格
涨跌幅

RVNC 简况

Revance Therapeutics, Inc.是一家生物技术公司。该公司专注于开发、制造和销售用于多种美容和治疗适应症的肉毒毒素产品。其TransMTS技术通过研究性药物候选产品（包括大肠杆菌毒素A外用凝胶（RT001）或RT001局部，及注射用大豆类毒素A（RT002）或RT002注射剂）递送A型肉毒杆菌毒素。其肉毒杆菌毒素 - 肽复合物具有有助于RT001和RT002的性能的两种组分。其TransMTS肽通过皮肤将毒素分子限制在靶位点。A型肉毒杆菌毒素提供药理作用的机制，并且负责在其临床试验中证明药物的作用。其TransMTS肽技术根据用于局部制剂还是用于可注射制剂而用于各种目的。
展开

微牛提供Revance Therapeutics Inc(NASDAQ-RVNC)的股票价格，实时市场报价，专业分析师评级，深度图表和免费的RVNC股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RVNC股票基本功能。